Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease-Reference-Cited by-同舟云学术

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease

Published:2020-10-23 Issue:43 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Higginbotham Lenora¹²³^ORCID,Ping Lingyan²³⁴^ORCID,Dammer Eric B.²³⁴^ORCID,Duong Duc M.²³⁴^ORCID,Zhou Maotian²³⁴^ORCID,Gearing Marla¹³⁵^ORCID,Hurst Cheyenne²^ORCID,Glass Jonathan D.¹²³^ORCID,Factor Stewart A.¹^ORCID,Johnson Erik C. B.¹²³^ORCID,Hajjar Ihab¹³^ORCID,Lah James J.¹²³^ORCID,Levey Allan I.¹²³^ORCID,Seyfried Nicholas T.¹²³⁴^ORCID

Affiliation:

1. Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

2. Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, USA.

3. Goizueta Alzheimer’s Disease Research Center, Emory University, Atlanta, GA, USA.

4. Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.

5. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Abstract

Integrative proteomic analysis identifies CSF biomarker panels linked to brain-based pathophysiologies in Alzheimer’s disease.

Funder

Foundation for the National Institutes of Health

National Institute on Aging

Accelerating Medicine Partnership for AD

Emory Goizueta Alzheimer’s Disease Research Center

NINDS Emory Neuroscience Core

Michael J. Fox Foundation for Parkinson’s Research

Alzheimer’s Association

Weston Brain Institute

Alzheimer’s Research UK

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference77 articles.

1. Evolving Relevance of Neuroproteomics in Alzheimer’s Disease

2. Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials

3. The Cellular Phase of Alzheimer’s Disease

4. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

5. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer’s disease biomarkers;Journal of Neuroscience Methods;2024-11

2. Target modulation of glycolytic pathways as a new strategy for the treatment of neuroinflammatory diseases;Ageing Research Reviews;2024-11

3. Unraveling the Protective Role of Oleocanthal and Its Oxidation Product, Oleocanthalic Acid, against Neuroinflammation;Antioxidants;2024-09-03

4. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease;Neurobiology of Disease;2024-09

5. Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression;Alzheimer's & Dementia;2024-08-27